Posted by Michael Wonder on 08 Jun 2022
European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma
8 June 2022 - Approval is based on the phase I/II GO29781 study, where Lunsumio induced high complete response rates, with the majority of complete responses lasting for at least 18 months in people with heavily pre-treated follicular lymphoma.
Roche today announced that the European Commission has granted conditional marketing authorisation for the CD20xCD3 T-cell engaging bispecific antibody Lunsumio (mosunetuzumab), for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
